---
schema_version: "secwatch.filing_event.v1"
accession: "0001477449-24-000083"
form_type: "8-K"
ticker: "TDOC"
cik: "0001477449"
company_name: "Teladoc Health, Inc."
filed_at: "2024-04-05T23:59:59+00:00"
generated_at: "2026-06-04T01:45:51.795599+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Teladoc CEO Jason Gorevic departs; CFO Mala Murthy named acting CEO

## Summary
- Jason Gorevic departs immediately; Board retains search firm for permanent successor.
- CFO Mala Murthy appointed acting CEO, retains CFO role; base salary raised to $750k, target bonus 120%, additional equity $1.1M.
- Company reaffirms Q1 2024 and full-year 2024 guidance, consistent with Feb 20 earnings release.
- Gorevic eligible for separation benefits per employment agreement subject to release.

## SEC filing metadata
- accession: 0001477449-24-000083
- form_type: 8-K
- ticker: TDOC
- cik: 0001477449
- company_name: Teladoc Health, Inc.
- filed_at: 2024-04-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1477449/000147744924000083/0001477449-24-000083-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1477449/000147744924000083/tdoc-20240405.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477449-24-000083
- JSON: https://secwatch.observer/filing/0001477449-24-000083.json
- Plain text: https://secwatch.observer/filing/0001477449-24-000083.txt

## Key facts
- Earnings Releases
  Teladoc Health, Inc. updated its quarter ended March 31, 2024 guidance (reaffirmed).
  - Period: quarter ended March 31, 2024
  - Guidance: reaffirmed
  - Result: preliminary results
  source text: On April 5, 2024, Teladoc Health, Inc. (“Teladoc Health” or the “Company”) announced that it continues to expect its outlook for the quarter ended March 31, 2024 and the year ending December 31, 2024 to be consistent with the outlook ranges disclosed in the Company’s earnings release on February 20, 2024. The financial results for the quarter ended March 31, 2024 are preliminary, unaudited and subject to change
  evidence_url: https://www.sec.gov/Archives/edgar/data/1477449/000147744924000083/0001477449-24-000083-index.htm
- Executive change
  Mala Murthy was appointed as acting Chief Executive Officer at Teladoc Health, Inc..
  - Action: appointed
  - Role: acting Chief Executive Officer
  source text: Teladoc Health announced the appointment of Mala Murthy to the position of acting Chief Executive Officer of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1477449/000147744924000083/0001477449-24-000083-index.htm
- Executive change
  Jason Gorevic departed as Chief Executive Officer at Teladoc Health, Inc..
  - Action: departed
  - Role: Chief Executive Officer
  source text: replacing Jason Gorevic, who will also depart from the Board of Directors of the Company as required by his employment agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1477449/000147744924000083/0001477449-24-000083-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.